EVA DE LAGO

Profesor Titular

Universidad Complutense de Madrid

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Eva de Lago is a Profesor Titular at Universidad Complutense de Madrid, Spain. Her research focuses on neurodegenerative diseases, particularly frontotemporal dementia and amyotrophic lateral sclerosis, as evidenced by her recent articles investigating drug repositioning, neuroprotective therapies, and the pathogenesis of these disorders. She explores therapeutic strategies, including the role of various receptors and ligands in disease progression.

Articles (11)

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

María Gómez Cañas

Profesora Ayudante Doctor

Universidad Complutense de Madrid Facultad de Medicina

SPAIN

View details

Pilar Rojas Lozano

Profesora Asociada

Universidad Complutense de Madrid

SPAIN

View details

Javier Fernández-Ruiz

Universidad Complutense de Madrid

SPAIN

View details

Patricia Boya

Full Professor

University of Fribourg

SWITZERLAND

View details

Carmen Rodriguez Cueto

Assistant Professor

Universidad Complutense de Madrid

SPAIN

View details

Manuel Guzmán

Universidad Complutense de Madrid

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

EVA DE LAGO

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia

Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

Discovery of Mitophagy Inhibitors with Therapeutic Potential in Different Familial Amyotrophic Lateral Sclerosis Mutations

New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Retinal Ganglion Cell Loss and Microglial Activation in a SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis

Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis

BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis

Inactivation of the CB 2 receptor accelerated the neuropathological deterioration in TDP‐43 transgenic mice, a model of amyotrophic lateral sclerosis

Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis

Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis

Targeting the CB 2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

Collaborators (6)

María Gómez Cañas

Pilar Rojas Lozano

Javier Fernández-Ruiz

Patricia Boya

Carmen Rodriguez Cueto

Manuel Guzmán

Make your next move.

EVA DE LAGO

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia

Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

Discovery of Mitophagy Inhibitors with Therapeutic Potential in Different Familial Amyotrophic Lateral Sclerosis Mutations

New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Retinal Ganglion Cell Loss and Microglial Activation in a SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis

Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson&rsquo;s Disease and Amyotrophic Lateral Sclerosis

BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis

Inactivation of the CB 2 receptor accelerated the neuropathological deterioration in TDP‐43 transgenic mice, a model of amyotrophic lateral sclerosis

Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis

Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis

Targeting the CB 2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

Collaborators (6)

María Gómez Cañas

Pilar Rojas Lozano

Javier Fernández-Ruiz

Patricia Boya

Carmen Rodriguez Cueto

Manuel Guzmán

Make your next move.

Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis